Open Access Open Access  Restricted Access Subscription or Fee Access

Neuromyelitis Optica Disorders: A Retrospective Observational Study: Experience of Tertiary Hospital in Central India

Priyanka V Kashyap, Sounak Chabri, Anshul Singh, Arpit Dhiren, Akanxa Yadav

Abstract


Background: NMOSD is a wide spectrum primary demyelinating syndrome of nervous system with varied clinical, serology and radiologic features. Objectives: We aim to study the vividness of clinical, serological and associated radiologic features of this disorder through retrospective analysis of the patients’ parameters presented to Neurology unit of AIIMS, Bhopal. Methods: It is a retrospective observational study from July 2020 till July 2022 in neurology. Results: 36 patients were assessed; of which, 18 patients suffice multiple sclerosis (MS) group, 10 patients in neuromyelitis optica (NMO) group and 2 and 6 patients in myelin oligodendrocyte glycoprotein antibody (MOGAD) and other unclassified demyelinating group respectively. Female predominance was most evident in NMO, followed by MS group. Duration of illness was shortest in MOGAD group (18.5±24.74 months) Extended Disability Status Scale (EDSS) was least in the MOGAD group (1.5). Bladder dysfunction associated with transverse myelitis (TM) was present in 80% in NMO group, and in 77.7% in MS group. Unilateral optic neuritis (ON) was commonest in MS group (27.77%) than NMO group (10%) but bilateral ON was most seen in MOGAD. Bilateral ON was seen in 11% of MS. Area postrema syndrome (APS) were noted in 30% of NMO patients. Imaging features were unique in MS (juxtacortical and cerebellar). Short segment myelitis was more common with MS group (66.67%) and conus involved in 50% of MOGAD group. Aquaporin antibody and MOG antibody were positive in all patients of the NMO and MOG group, 88.89% of MS patients had cerebrospinal fluid (CSF) oligoclonal band (OCB) positive. Conclusion: NMOSD has distinct features, radiologic and serum biomarkers that help to subgroup it.

Keywords


Neuromyeltis optica, multiple sclerosis, myelin oligodendrocyte glycoprotein antibodies, optic neuritis

Full Text:

PDF

References


Papp V, Illes Z, Magyari M, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology. 2018; 91(24): E2265–E2275. doi:10.1212/WNL.000000 0000006645

Jonsson DI, Sveinsson O, Hakim R, et al. Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study. Neurology. 2019; 93(2): E181–E189. doi:10.1212/WNL.000000000 00077463.

Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–89.

Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805–815.

Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009; 256(11): 1891–1898.

Mealy M, Wingerchuck D, Greenberg B, et al. Epidemiology of neuromyelitis optica in the United States, a multicenter analysis. Arch Neurol. 2012; 69(9): 1176–1180.

Pandit L, Mustafa S. Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Ann Indian Acad Neurol. 2013; 16(4): 572–576.

Siritho S, Nakashima I, Takahashi T, et al. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. Neurology. 2011; 77(9): 827–834.

Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011; 76(18): 1589–1595.

Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. J Neurol Sci. 2009; 286(1–2): 58–61.

Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology. 2010; 74(9): 736–742.

Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012; 9: 14.

Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2013; 20(8): 1086– 1094.

Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 2013; 70(11): 1375–1381.

Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology. 2010; 75(12): 1084–1088.

Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler J. 2015; 21(7): 845–853. DOI: 10.1177/ 1352458515572406.

Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol. 2001; 29(5): 312–315. [PubMed] [Google Scholar] [Ref list]

Kim HJ, Park KA. Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. Korean J Ophthalmol. 2019; 33(1): 82–90. https://doi.org/10.3341/kjo.2018.0050.

Joshi PB, Shah SD, et al. A Study of Neuromyelitis Optica Spectrum Disorders (NMOSD): Disease Pattern Based on Antibody Status. Neurol India. 2022; 70(3): 1131–6.

Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63(3): 390–6.

Marignier R, Bernard‐Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin‐4 antibody‐negative neuromyelitis optica: Distinct assay sensitivity‐dependent entity. Neurology. 2013; 80(24): 2194–2200.

Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, et al. Neuromyelitisoptica spectrum disorders with aquaporin-4 and myelin-oligodendrocyteglyco-protein antibodies: a comparative study. JAMA Neurol. 2014; 71(3): 276–283.

Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012; 44(9): 1519–1530.

Sherman E, Han MH. Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. Curr Treat Options Neurol. 2015; 17(11): 48.

Takai Y, Misu T, Nakashima I, et al. Two cases of lumbosacral myeloradiculitis with anti- aquaporin-4 antibody. Neurology. 2012; 79(17): 1826–1828.

BukhariW, Clarke L. The clinical profile of NMOSD in Australia and New Zealand. J Neurol. 2020 May; 267(5): 1431–1443. doi: 10.1007/s00415-020-09716-4. Epub 2020 Jan 31.

Khedr, et al. Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns. Egypt J Neurol Psychiatry Neurosurg. 2021; 57: 155.

Salama S, Marouf H, et al. Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. J Neuroimmunol. 2018; 324: 22–25. https:// doi. org/ 10. 1016/j. jneur oim. 2018. 08. 014.

Fan R, Zhang Y, et al. Serum antinuclear antibodies associate with worse prognosis in AQP4- positive neuromyelitis optica spectrum disorder Brain Behav. 2021; 11(1): e01865. 1–8 https://doi.org/10.1002/brb3.1865.

Fukuda TG, Silva TF, et al. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol. 2022; 22(1): 95. https://doi.org/10.1186/s12883-022-02621-5

Wu J-S, Zhang M-N, et al. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatr. 2008; 79(9): 1022–1026. doi: 10.1136/jnnp.2007.131177. [PubMed] [CrossRef] [Google Scholar] [Ref list]

Otto Jesus Hernandez Fustes, Cláudia SK, et al. Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. J Cent Nerv Syst Dis. 2021 Dec; 13: 11795735211057315(5p).


Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Health Professions